← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Navigen, Inc.
Salt Lake City, UT
$31,092,216
Total funding
32
Grants
Funding over time
peak $4.9M · FY2008–22$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$31,092,216 · 32
By mechanism
R44$14,488,736 · 7
R43$5,968,532 · 18
U44$3,000,000 · 1
SB1$3,000,000 · 1
R01$2,817,486 · 2
R56$1,334,888 · 2
Investigators at Navigen, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Largest grants
Therapeutic D-peptide Inhibitor of HIV Entry$1,000,000
R44 · FY2015 · AI
Therapeutic D-peptide Inhibitor of HIV Entry$1,000,000
SB1 · FY2017 · AI
A Phase Ia/Ib Clinical Study of HIV Entry Inhibitor CPT31:Single and Multiple Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults anAdults with HIV$1,000,000
U44 · FY2022 · AI
A Phase Ia/Ib Clinical Study of HIV Entry Inhibitor CPT31:Single and Multiple Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults anAdults with HIV$1,000,000
U44 · FY2021 · AI
Therapeutic D-peptide Inhibitor of HIV Entry$1,000,000
SB1 · FY2018 · AI
Protease-resistant D-peptide Inhibitors of Ebola Virus Entry$1,000,000
R44 · FY2016 · AI
A Phase Ia/Ib Clinical Study of HIV Entry Inhibitor CPT31:Single and Multiple Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults anAdults with HIV$1,000,000
U44 · FY2020 · AI
Therapeutic D-peptide Inhibitor of HIV Entry$1,000,000
SB1 · FY2019 · AI
Protease-resistant D-peptide Inhibitors of Ebola Virus Entry$1,000,000
R44 · FY2015 · AI
Therapeutic D-peptide Inhibitor of HIV Entry$1,000,000
R44 · FY2014 · AI
Therapeutic D-peptide Inhibitor of HIV Entry$1,000,000
R44 · FY2013 · AI
Preclinical development of a potent D-peptide RSV inhibitor$999,998
R44 · FY2017 · AI
Preclinical development of a potent D-peptide RSV inhibitor$999,998
R44 · FY2018 · AI
Preclinical development of a potent D-peptide RSV inhibitor$992,263
R44 · FY2016 · AI
Protease-resistant D-peptide Inhibitors of Ebola Virus Entry$894,941
R44 · FY2017 · AI
ARF6 Inhibitors for Treatment of Acute Lung Injury$889,461
R44 · FY2017 · HL
Depot formulation of a D-peptide HIV entry inhibitor$826,272
R01 · FY2017 · AI
ARF6 Inhibitors for Treatment of Acute Lung Injury$817,279
R44 · FY2018 · HL
Slit2N for the Treatment of Viral Hemorrhagic Fever$809,980
R56 · FY2012 · AI
Blocking a novel cytokine signaling pathway for the treatment of rheumatoid arthr$755,418
R44 · FY2015 · AR